The Organic Chemistry Of Drug Design And Drug Action by Richard B. SilvermanThe Organic Chemistry Of Drug Design And Drug Action by Richard B. Silverman

The Organic Chemistry Of Drug Design And Drug Action

byRichard B. Silverman, Mark W. HolladayEditorRichard B. Silverman

Hardcover | May 27, 2014

Pricing and Purchase Info

$122.03 online 
$155.19 list price save 21%
Earn 610 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


The Organic Chemistry of Drug Design and Drug Action, Third Edition,represents a unique approach to medicinal chemistry based on physical organic chemical principles and reaction mechanisms that rationalize drug action, which allows reader to extrapolate those core principles and mechanisms to many related classes of drug molecules.

This new edition includes updates to all chapters, including new examples and references. It reflects significant changes in the process of drug design over the last decade and preserves the successful approach of the previous editions while including significant changes in format and coverage.

This text is designed for undergraduate and graduate students in chemistry studying medicinal chemistry or pharmaceutical chemistry; research chemists and biochemists working in pharmaceutical and biotechnology industries.

  • Updates to all chapters, including new examples and references
  • Chapter 1 (Introduction): Completely rewritten and expanded as an overview of topics discussed in detail throughout the book
  • Chapter 2 (Lead Discovery and Lead Modification): Sections on sources of compounds for screening including library collections, virtual screening, and computational methods, as well as hit-to-lead and scaffold hopping; expanded sections on sources of lead compounds, fragment-based lead discovery, and molecular graphics; and deemphasized solid-phase synthesis and combinatorial chemistry
  • Chapter 3 (Receptors): Drug-receptor interactions, cation-À and halogen bonding; atropisomers; case history of the insomnia drug suvorexant
  • Chapter 4 (Enzymes): Expanded sections on enzyme catalysis in drug discovery and enzyme synthesis
  • Chapter 5 (Enzyme Inhibition and Inactivation): New case histories:
    • for competitive inhibition, the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib and Abelson kinase inhibitor, imatinib
    • for transition state analogue inhibition, the purine nucleoside phosphorylase inhibitors, forodesine and DADMe-ImmH, as well as the mechanism of the multisubstrate analog inhibitor isoniazid
    • for slow, tight-binding inhibition, the dipeptidyl peptidase-4 inhibitor, saxagliptin
  • Chapter 7 (Drug Resistance and Drug Synergism): This new chapter includes topics taken from two chapters in the previous edition, with many new examples
  • Chapter 8 (Drug Metabolism): Discussions of toxicophores and reactive metabolites
  • Chapter 9 (Prodrugs and Drug Delivery Systems): Discussion of antibody drug conjugates
Professor Richard B. Silverman received his B.S. degree in chemistry from The Pennsylvania State University in 1968 and his Ph.D. degree in organic chemistry from Harvard University in 1974 (with time off for a two-year military obligation from 1969-1971). After two years as a NIH postdoctoral fellow in the laboratory of the late Profe...
Title:The Organic Chemistry Of Drug Design And Drug ActionFormat:HardcoverDimensions:536 pages, 9.41 × 7.24 × 0.98 inPublished:May 27, 2014Publisher:Academic PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0123820308

ISBN - 13:9780123820303

Look for similar items by category:


Table of Contents

1. Introduction 1.1. Overview 1.2. Drugs Discovered without Rational Design 1.2.1. Medicinal Chemistry Folklore 1.2.2. Discovery of Penicillins 1.2.3. Discovery of Librium 1.2.4. Discovery of Drugs through Metabolism Studies 1.2.5. Discovery of Drugs through Clinical Observations 1.3. Overview of Modern Rational Drug Design 1.3.1. Overview of Drug Targets 1.3.2. Identification and Validation of Targets for Drug Discovery 1.3.3. Alternatives to Target-Based Drug Discovery 1.3.4. Lead Discovery 1.3.5. Lead Modification (Lead Optimization) Potency Selectivity Absorption, Distribution, Metabolism, and Excretion (ADME) Intellectual Property Position 1.3.6. Drug Development Preclinical Development Clinical Development (Human Clinical Trials) Regulatory Approval to Market the Drug 1.4. Epilogue 1.5. General References 1.6. Problems References2. Lead Discovery and Lead Modification 2.1. Lead Discovery 2.1.1. General Considerations 2.1.2. Sources of Lead Compounds Endogenous Ligands Other Known Ligands Screening of Compounds Sources of Compounds for Screening Natural Products Medicinal Chemistry Collections and Other "Handcrafted" Compounds High-Throughput Organic Synthesis Solid-Phase Library Synthesis Solution-Phase Library Synthesis Evolution of HTOS Drug-Like, Lead-Like, and Other Desirable Properties of Compounds for Screening Random Screening Targeted (or Focused) Screening, Virtual Screening, and Computational Methods in Lead Discovery Virtual Screening Database Virtual Screening Hypothesis Hit-To-Lead Process Fragment-based Lead Discovery 2.2. Lead Modification 2.2.1. Identification of the Active Part: The Pharmacophore 2.2.2. Functional Group Modification 2.2.3. Structure Activity Relationships 2.2.4. Structure Modifications to Increase Potency, Therapeutic Index, and ADME Properties Homologation Chain Branching Bioisosterism Conformational Constraints and Ring-Chain Transformations Peptidomimetics 2.2.5. Structure Modifications to Increase Oral Bioavailability and Membrane Permeability Electronic Effects: The Hammett Equation Lipophilicity Effects Importance of Lipophilicity Measurement of Lipophilicities Computer Automation of log P Determination Membrane Lipophilicity Balancing Potency of Ionizable Compounds with Lipophilicity and Oral Bioavailability Properties that Influence Ability to Cross the Blood Brain Barrier Correlation of Lipophilicity with Promiscuity and Toxicity 2.2.6. Computational Methods in Lead Modification Overview Quantitative Structure Activity Relationships (QSARs) Historical Overview. Steric Effects: The Taft Equation and Other Equations Methods Used to Correlate Physicochemical Parameters with Biological Activity Hansch Analysis: A Linear Multiple Regression Analysis Manual Stepwise Methods: Topliss Operational Schemes and Others Batch Selection Methods: Batchwise Topliss Operational Scheme, Cluster Analysis, and Others Free and Wilson or de Novo Method Computational Methods for ADME Descriptors Scaffold Hopping Molecular Graphics-Based Lead Modification 2.2.7. Epilogue 2.3. General References 2.4. Problems References3. Receptors 3.1. Introduction 3.2. Drug Receptor Interactions 3.2.1. General Considerations 3.2.2. Important Interactions (Forces) Involved in the Drug Receptor Complex Covalent Bonds Ionic (or Electrostatic) Interactions Ion Dipole and Dipole Dipole Interactions Hydrogen Bonds Charge Transfer Complexes Hydrophobic Interactions Cation À Interaction Halogen Bonding van der Waals or London Dispersion Forces Conclusion 3.2.3. Determination of Drug Receptor Interactions 3.2.4. Theories for Drug Receptor Interactions Occupancy Theory Rate Theory Induced-Fit Theory Macromolecular Perturbation Theory Activation Aggregation Theory The Two-State (Multistate) Model of Receptor Activation 3.2.5. Topographical and Stereochemical Considerations Spatial Arrangement of Atoms Drug and Receptor Chirality Diastereomers Conformational Isomers Atropisomers Ring Topology 3.2.6. Case History of the Pharmacodynamically Driven Design of a Receptor Antagonist: Cimetidine 3.2.7. Case History of the Pharmacokinetically Driven Design of Suvorexant 3.3. General References 3.4. Problems References4. Enzymes 4.1. Enzymes as Catalysts 4.1.1. What are Enzymes? 4.1.2. How do Enzymes Work? Specificity of Enzyme-Catalyzed Reactions Binding Specificity Reaction Specificity Rate Acceleration 4.2. Mechanisms of Enzyme Catalysis 4.2.1. Approximation 4.2.2. Covalent Catalysis 4.2.3. General Acid Base Catalysis 4.2.4. Electrostatic Catalysis 4.2.5. Desolvation 4.2.6. Strain or Distortion 4.2.7. Example of the Mechanisms of Enzyme Catalysis 4.3. Coenzyme Catalysis 4.3.1. Pyridoxal 52 -Phosphate Racemases Decarboxylases Aminotransferases (Formerly Transaminases) PLP-Dependent ² -Elimination 4.3.2. Tetrahydrofolate and Pyridine Nucleotides 4.3.3. Flavin Two-Electron (Carbanion) Mechanism Carbanion Followed by Two One-Electron Transfers One-Electron Mechanism Hydride Mechanism 4.3.4. Heme 4.3.5. Adenosine Triphosphate and Coenzyme A 4.4. Enzyme Catalysis in Drug Discovery 4.4.1. Enzymatic Synthesis of Chiral Drug Intermediates 4.4.2. Enzyme Therapy 4.5. General References 4.6. Problems References5. Enzyme Inhibition and Inactivation 5.1. Why Inhibit an Enzyme? 5.2. Reversible Enzyme Inhibitors 5.2.1. Mechanism of Reversible Inhibition 5.2.2. Selected Examples of Competitive Reversible Inhibitor Drugs Simple Competitive Inhibition Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Cancer Discovery and Optimization of EGFR Inhibitors Stabilization of an Inactive Conformation: Imatinib, an Antileukemia Drug The Target: Bcr-Abl, a Constitutively Active Kinase Lead Discovery and Modification Binding Mode of Imatinib to Abl Kinase Inhibition of Other Kinases by Imatinib Alternative Substrate Inhibition: Sulfonamide Antibacterial Agents (Sulfa Drugs) Lead Discovery Lead Modification Mechanism of Action 5.2.3. Transition State Analogs and Multisubstrate Analogs Theoretical Basis Transition State Analogs Enalaprilat Pentostatin Forodesine and DADMe-ImmH Multisubstrate Analogs 5.2.4. Slow, T ight-Binding Inhibitors Theoretical Basis Captopril, Enalapril, Lisinopril, and Other Antihypertensive Drugs Humoral Mechanism for Hypertension Lead Discovery Lead Modification and Mechanism of Action Dual-Acting Drugs: Dual-Acting Enzyme Inhibitors Lovastatin (Mevinolin) and Simvastatin, Antihypercholesterolemic Drugs Cholesterol and Its Effects Lead Discovery Mechanism of Action Lead Modification Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor and Antidiabetes Drug 5.2.5. Case History of Rational Drug Design of an Enzyme Inhibitor: Ritonavir Lead Discovery Lead Modification 5.3. Irreversible Enzyme Inhibitors 5.3.1. Potential of Irreversible Inhibition 5.3.2. Affinity Labeling Agents Mechanism of Action Selected Affinity Labeling Agents Penicillins and Cephalosporins/Cephamycins Aspirin 5.3.3. Mechanism-Based Enzyme Inactivators Theoretical Aspects Potential Advantages in Drug Design Relative to Affinity Labeling Agents Selected Examples of Mechanism-Based Enzyme Inactivators Vigabatrin, an Anticonvulsant Drug Eflornithine, an Antiprotozoal Drug and Beyond Tranylcypromine, an Antidepressant Drug Selegiline (l-Deprenyl) and Rasagiline: Antiparkinsonian Drugs 5-Fluoro-22 -deoxyuridylate, Floxuridine, and 5-Fluorouracil: Antitumor Drugs 5.4. General References 5.5. Problems References6. DNA-Interactive Agents 6.1. Introduction 6.1.1. Basis for DNA-Interactive Drugs 6.1.2. Toxicity of DNA-Interactive Drugs 6.1.3. Combination Chemotherapy 6.1.4. Drug Interactions 6.1.5. Drug Resistance 6.2. DNA Structure and Properties 6.2.1. Basis for the Structure of DNA 6.2.2. Base Tautomerization 6.2.3. DNA Shapes 6.2.4. DNA Conformations 6.3. Classes of Drugs that Interact with DNA 6.3.1. Reversible DNA Binders External Electrostatic Binding Groove Binding Intercalation and Topoisomerase-Induced DNA Damage Amsacrine, an Acridine Analog Dactinomycin, the Parent Actinomycin Analog Doxorubicin (Adriamycin) and Daunorubicin (Daunomycin), Anthracycline Antitumor Antibiotics Bis-intercalating Agents 6.3.2. DNA Alkylators Nitrogen Mustards Lead Discovery Chemistry of Alkylating Agents Lead Modification Ethylenimines Methanesulfonates (+)-CC-1065 and Duocarmycins Metabolically Activated Alkylating Agents Nitrosoureas Triazene Antitumor Drugs Mitomycin C Leinamycin 6.3.3. DNA Strand Breakers Anthracycline Antitumor Antibiotics Bleomycin Tirapazamine Enediyne Antitumor Antibiotics Esperamicins and Calicheamicins Dynemicin A Neocarzinostatin (Zinostatin) Sequence Specificity for DNA-Strand Scission 6.4. General References 6.5. Problems References7. Drug Resistance and Drug Synergism 7.1. Drug Resistance 7.1.1. What is Drug Resistance? 7.1.2. Mechanisms of Drug Resistance Altered Target Enzyme or Receptor Overproduction of the Target Enzyme or Receptor Overproduction of the Substrate or Ligand for the Target Protein Increased Drug-Destroying Mechanisms Decreased Prodrug-Activating Mechanism Activation of New Pathways Circumventing the Drug Effect Reversal of Drug Action Altered Drug Distribution to the Site of Action 7.2. Drug Synergism (Drug Combination) 7.2.1. What is Drug Synergism? 7.2.2. Mechanisms of Drug Synergism Inhibition of a Drug-Destroying Enzyme Sequential Blocking Inhibition of Targets in Different Pathways Efflux Pump Inhibitors Use of Multiple Drugs for the Same Target 7.3. General References 7.4. Problems References8. Drug Metabolism 8.1. Introduction 8.2. Synthesis of Radioactive Compounds 8.3. Analytical Methods in Drug Metabolism 8.3.1. Sample Preparation 8.3.2. Separation 8.3.3. Identification 8.3.4. Quantification 8.4. Pathways for Drug Deactivation and Elimination 8.4.1. Introduction 8.4.2. Phase I Transformations Oxidative Reactions Aromatic Hydroxylation Alkene Epoxidation Oxidations of Carbons Adjacent to sp2 Centers Oxidation at Aliphatic and Alicyclic Carbon Atoms Oxidations of Carbon Nitrogen Systems Oxidations of Carbon Oxygen Systems Oxidations of Carbon Sulfur Systems Other Oxidative Reactions Alcohol and Aldehyde Oxidations Reductive Reactions Carbonyl Reduction Nitro Reduction Azo Reduction Azido Reduction Tertiary Amine Oxide Reduction Reductive Dehalogenation Carboxylation Reaction Hydrolytic Reactions 8.4.3. Phase II Transformations: Conjugation Reaction Introduction Glucuronic Acid Conjugation Sulfate Conjugation Amino Acid Conjugation Glutathione Conjugation Water Conjugation Acetyl Conjugation Fatty Acid and Cholesterol Conjugation Methyl Conjugation 8.4.4. Toxicophores and Reactive Metabolites (RMs) 8.4.5. Hard and Soft (Antedrugs) Drugs 8.5. General References 8.6. Problems References9. Prodrugs and Drug Delivery Systems 9.1. Enzyme Activation of Drugs 9.1.1. Utility of Prodrugs Aqueous Solubility Absorption and Distribution Site Specificity Instability Prolonged Release Toxicity Poor Patient Acceptability Formulation Problems 9.1.2. Types of Prodrugs 9.2. Mechanisms of Drug Inactivation 9.2.1. Carrier-Linked Prodrugs Carrier Linkages for Various Functional Groups Alcohols, Carboxylic Acids, and Related Amines and Amidines Sulfonamides Carbonyl Compounds Examples of Carrier-Linked Bipartite Prodrugs Prodrugs for Increased Water Solubility Prodrugs for Improved Absorption and Distribution Prodrugs for Site Specificity Prodrugs for Stability Prodrugs for Slow and Prolonged Release Prodrugs to Minimize Toxicity Prodrugs to Encourage Patient Acceptance Prodrugs to Eliminate Formulation Problems Macromolecular Drug Carrier Systems General Strategy Synthetic Polymers Poly(± -Amino Acids) Other Macromolecular Supports Tripartite Prodrugs Mutual Prodrugs (also called Codrugs) 9.2.2. Bioprecursor Prodrugs Origins Proton Activation: An Abbreviated Case History of the Discovery of Omeprazole Hydrolytic Activation Elimination Activation Oxidative Activation